With commitment to high quality innovation and cutting-edge technologies, we make scientific discoveries to serve humankind and save and improve lives.
We develop new therapies for multiple diseases with unmet needs through our pioneering research and innovative and disruptive drug discovery technologies.
SignaBlok, Inc. was founded in 2009 to commercialize recent key breakthroughs in our understanding of membrane receptor signaling and our ability to control and influence this process. Inhibition of receptor signaling is often one of the most effective ways of preventing and treating disease. Unfortunately, the commonly pursued strategy of inhibiting receptor-ligand binding requires expensive, intravenous, large protein-based medicines with severe and often life-threatening side effects.
SignaBlok’s innovative and disruptive drug discovery technology, which is based on our novel model of transmembrane signaling, the SCHOOL (Signaling Chain HOmoOLigomerization) model, prevents communication via the cell membrane between the ligand-binding and signaling subunits. This “Freedom to Bind, Not to Signal” new therapeutic approach of silencing intracellular signals is a more targeted and efficient method, thereby enabling smaller molecules and doses while avoiding serious side effects. Recent research breakthroughs revealed that viruses use the SCHOOL-like mechanisms to enter human cells without triggering the self-defense response. SignaBlok transforms viral immune evasion strategies optimized over the millennia to therapeutic strategies that require similar functionalities.
The SCHOOL technology enables development of next generation therapeutics to treat a variety of large market diseases with unmet needs: thrombosis, sepsis, dermatitis, arthritis, Crohn's disease, lupus, multiple sclerosis, organ transplantation, etc. Our commitment to high quality innovation, science and management expertise, encouraging results, our impressive IP portfolio, our growing involvement in international efforts to address unmet medical needs place us on a fast-track to success.
